6 studies found for:    SB-728-T
Show Display Options
Rank Status Study
1 Recruiting Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
Condition: HIV
Intervention: Genetic: SB-728-T
2 Completed Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Conditions: HIV;   HIV Infection
Intervention: Biological: SB-728-T
3 Completed Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
Conditions: HIV Infection;   HIV Infections
Intervention: Genetic: SB-728-T
4 Recruiting Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Genetic: SB-728mR-T;   Drug: Cyclophosphamide
5 Recruiting A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: ZFN Modified CD4+ T Cells;   Drug: Cyclophosphamide
6 Completed Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV
Conditions: HIV;   HIV Infections
Interventions: Biological: ZFN modified T cells;   Other: Structured Treatment Interruption

Indicates status has not been verified in more than two years